Today, we’re thrilled to announce that Healthcare Tech Outlook has named Golden Helix among the Top 10 Genetic Diagnostics Companies of 2020. This recognition places us alongside a remarkable group of companies that are leading innovation in genomics, diagnostics, and precision medicine. We are honored to receive this distinction and grateful for the opportunity to share our story in the accompanying feature article.
In their profile, Healthcare Tech Outlook highlights the core strengths that have defined Golden Helix for over two decades—robust bioinformatics tools, customer-driven development, and our mission to empower scientists and clinicians around the globe. Our platform supports advanced genetic analysis for both germline and somatic workflows, helping researchers and clinicians make confident decisions in cancer diagnostics, rare disease detection, and population-scale genomic studies.
You can read the full article and learn more about why Golden Helix was selected, here.
Of course, awards like this are never earned in isolation. We owe immense thanks to our global community of customers, research collaborators, and partners who continue to support and inspire us. Your work drives our innovation, and we’re proud to be part of the discoveries you’re making every day.
This recognition joins a growing list of recent achievements, including:
- Golden Helix Named to the 2019 Inc. 5000 List of Fastest-Growing Private Companies
- GHP Magazine’s 2020 Biotechnology Awards
- Top 10 World’s Most Trust Worthy Bioanalysis Companies in 2020
As we look ahead, we remain committed to delivering cutting-edge bioinformatics solutions that fuel life-saving breakthroughs in genomic medicine. Thank you for being part of our journey.